racecadotril

racecadotril. It is an antidiarrheal medication used in the management of acute diarrhea in adults and children. The drug acts as a selective inhibitor of the enzyme enkephalinase, which is primarily located in the intestine. This mechanism allows for a reduction in fluid and electrolyte secretion into the bowel without affecting gastrointestinal motility.

Medical uses

Racecadotril is indicated for the symptomatic treatment of acute diarrhea in conjunction with oral rehydration therapy. Clinical studies, including those published in *The New England Journal of Medicine*, have demonstrated its efficacy in reducing the duration and severity of watery stools in both pediatric and adult populations. It is often compared to other agents like loperamide, but it does not carry the same risk of causing constipation or promoting bacterial overgrowth, as it is not an opioid. Its use is recommended by organizations such as the European Society for Paediatric Gastroenterology Hepatology and Nutrition.

Adverse effects

The adverse drug reaction profile of racecadotril is generally considered mild. The most commonly reported side effects include headache, skin rash, and dizziness. Serious adverse events are rare but may involve angioedema or severe hypersensitivity reactions, necessitating discontinuation of therapy. Its safety profile in children has been extensively reviewed by regulatory bodies like the European Medicines Agency and the World Health Organization.

Pharmacology

Racecadotril is a prodrug that is rapidly hydrolyzed in the plasma to its active metabolite, thiorphan. Thiorphan is a potent and selective inhibitor of membrane metallo-endopeptidase, also known as enkephalinase. This enzyme is responsible for the degradation of endogenous enkephalins in the gastrointestinal tract. By inhibiting enkephalinase, the drug increases local enkephalin levels, which in turn activate delta-opioid receptors on enterocytes. This activation reduces the secretion of water and electrolytes into the intestinal lumen by modulating intracellular cyclic AMP levels, without impacting intestinal motility or absorption.

History

The development of racecadotril followed research into enkephalinase inhibitors during the late 1970s and 1980s by scientists at the French Institute of Health and Medical Research. It was first synthesized by the pharmaceutical company Bioprojet and received marketing authorization in France in 1990. Subsequent approvals followed across Europe, Asia, and Latin America. It has been the subject of numerous clinical trials, including large-scale studies coordinated by the World Health Organization's Diarrhoeal Disease Control Programme.

Society and culture

Racecadotril is marketed under various brand names including Hidrasec and Tiorfan in many countries. It is available as an over-the-counter drug in some nations, while in others, like the United Kingdom, it remains a prescription-only medication. The drug has been included in the World Health Organization Model List of Essential Medicines for children, highlighting its global health importance. Its role in managing outbreaks during humanitarian crises has been noted by agencies like Médecins Sans Frontières.

Category:Antidiarrheals Category:Prodrugs Category:World Health Organization essential medicines